Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-course chemoradiotherapy followed by NALIRIFOX in neoadjuvant treatment for locally advanced low rectal cancer (pMMR/MSS)
ChiCTR2500110644Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2025
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nanoliposomal irinotecan in rectal cancer (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Rate of complete response. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR2500110644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110644.